Vladimir Berthaud
Infectious Disease · Nashville, TNNPI 1790763019
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,278 of the $3,121 with a category attached, or 73.0%. 8 manufacturers reported payments, led by Merck at 57.1% of the total. 2025 is the largest year on record at $1,798, more than ten times the $44 reported in 2019.
Across 26 payments — averaging $120.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Modernatx, Inc.$1K
- Viiv Healthcare Company$117
- Janssen Products, LP$99
- AbbVie$42
- EMD Serono, Inc.$21
- plus $32 from 2 others
Across 155 payments — averaging $4712.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$599K
- Gilead$78K
- GSK$38K
- Viiv Healthcare Company$16K
What the payments were for
- Travel & lodging$2,27873%
- Food & beverage$72723%
- Education$1154%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 9 | $1,781 |
| Modernatx, Inc. | 4 | $1,029 |
| Viiv Healthcare Company | 6 | $117 |
| Janssen Products, LP | 1 | $99 |
| AbbVie | 2 | $42 |
| EMD Serono, Inc. | 1 | $21 |
| Insmed, Inc. | 1 | $16 |
| Johnson & Johnson | 2 | $16 |
How this compares
$3,121 in reported general payments places this provider in the 80th percentile of 156 infectious disease providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 155 | $601,145 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 60 | $228,981 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 42 | $144,177 |
| TivicayDolutegravir Sodium | 50 | $110,030 |
| DovatoDolutegravir Sodium/Lamivudine | 17 | $49,834 |
| DescovyEmtricitabine/Tenofov Alafenam | 18 | $38,727 |
| Darunavir | 13 | $14,222 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $12,017 |
| PremarinEstrogens, Conjugated | 11 | $4,632 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $3,940 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 93 | $2,938 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $2,173 |
| LantusInsulin Glargine,hum.Rec.Anlog | 20 | $1,242 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 12 | $965 |
| Gabapentin | 76 | $814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyTivicay, Dovato | $117 | $159,86467 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 infectious disease providers in Tennessee.
Other infectious disease in Nashville
- John KoetheNashville$91K
- Elizabeth PhillipsNashville$71K
- Kassem BourgiNashville$34K
- Celestine WanjallaNashville$24K
- Sean KellyNashville$17K
- David AronoffNashville$17K
- William SchaffnerNashville$16K
- Juli HortonNashville$14K
- Maricar MalinisNashville$14K
- Paul BryantNashville$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.